4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 6,244 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMTGet Free Report) insider Scott Bizily sold 6,244 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $27.50, for a total transaction of $171,710.00. Following the completion of the transaction, the insider now owns 1,737 shares in the company, valued at $47,767.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $27.85 on Tuesday. The company’s fifty day moving average price is $19.69 and its 200-day moving average price is $15.81. 4D Molecular Therapeutics, Inc. has a one year low of $9.44 and a one year high of $35.61. The company has a market capitalization of $1.19 billion, a PE ratio of -10.20 and a beta of 2.63.

Analyst Ratings Changes

FDMT has been the topic of a number of recent research reports. Cantor Fitzgerald assumed coverage on 4D Molecular Therapeutics in a report on Tuesday, October 24th. They issued an “overweight” rating and a $32.00 target price on the stock. Royal Bank of Canada boosted their price objective on 4D Molecular Therapeutics from $25.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. BMO Capital Markets lifted their price target on shares of 4D Molecular Therapeutics from $50.00 to $70.00 and gave the company an “outperform” rating in a report on Monday, February 5th. The Goldman Sachs Group reissued a “buy” rating and issued a $81.00 price objective on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 7th. Finally, Leerink Partnrs upgraded shares of 4D Molecular Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $39.44.

Check Out Our Latest Stock Analysis on FDMT

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. boosted its holdings in shares of 4D Molecular Therapeutics by 35.6% during the 3rd quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock valued at $52,998,000 after purchasing an additional 1,093,680 shares during the last quarter. VR Adviser LLC bought a new position in 4D Molecular Therapeutics during the second quarter valued at approximately $54,210,000. BlackRock Inc. grew its holdings in 4D Molecular Therapeutics by 14.3% during the 2nd quarter. BlackRock Inc. now owns 2,914,430 shares of the company’s stock valued at $52,664,000 after buying an additional 363,695 shares in the last quarter. Deep Track Capital LP increased its stake in 4D Molecular Therapeutics by 21.9% in the 2nd quarter. Deep Track Capital LP now owns 2,778,107 shares of the company’s stock worth $50,200,000 after acquiring an additional 500,000 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of 4D Molecular Therapeutics by 0.4% during the 2nd quarter. State Street Corp now owns 2,050,430 shares of the company’s stock worth $37,051,000 after acquiring an additional 8,241 shares in the last quarter.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy.

Recommended Stories

Insider Buying and Selling by Quarter for 4D Molecular Therapeutics (NASDAQ:FDMT)

Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.